Using aliphatic polyamine injections to maintain column chromatography performance
Aliphatic polyamines like spermidine are used to condense trapped nucleic acids and clear microbial contamination, addressing column performance issues by enhancing recovery and separation in chromatography.
Patent Information
- Application Number
- PCT/IB2026/054486
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Chromatography columns experience performance deterioration due to trapped or unfolded nucleic acid molecules, column clogging, and microbial contamination, leading to poor recovery and separation, with existing regeneration methods being ineffective.
Injections of aliphatic polyamines like spermidine, norspermidine, and spermine are used to condense unfolded nucleic acids and clear microbial contamination, releasing trapped residues and maintaining column performance.
The method effectively removes trapped biological macromolecules and LNPs, reduces bacterial contamination, and restores column performance by ensuring consistent recovery and separation.
Smart Images

Figure IMGF000009_0001 
Figure IMGF000009_0002 
Figure IMGF000013_0001
Abstract
Description
International W-4803-W001 USING ALIPHATIC POLYAMINE INJECTIONS TO MAINTAIN COLUMN CHROMATOGRAPHY PERFORMANCECross-Reference to Related Applications
[0001] This application claims the benefit of and priority to U.S. Provisional Application No. 63 / 801 ,409, filed May 7, 2025, the entire disclosure of which is incorporated herein by reference.Field of Technology
[0002] The present disclosure relates generally to methods of restoring column chromatography performance using injections of one or more aliphatic polyamines such as spermidine, norspermidine, and spermine.Background
[0003] Liquid chromatography methods involve high pressure separations where the molecules are forced to move through the narrow spaces of column stationary phase. In methods like slalom chromatography, the back pressure (-10,000 psi or higher) generated inside the column is used to resolve the molecules based on their stretchability and relaxation. Separation happens when molecules are forced through narrow and tortuous open spaces around the closely packed high strength spherical beads. The laminar flow generated through these narrow channels unfold or extend the analyte, such as DNA molecules. Longer molecules with extended conformations face higher difficulty in moving through narrow spaces compared to shorter nucleic acid molecules leading to size-based separation. Such increased difficulty can lead to decreased recovery, column clogging and deterioration in column performance.
[0004] Although longer molecules are more prone to such behavior, the free movement of shorter molecules can depend on their shape as well and their ability to navigate through the column. In such situations, molecules irrespective of their size may not elute from the column leading to poor recovery. Poor recovery can also impact separations within a size exclusion chromatography column. Even though the pressures applicable to size exclusion chromatography are lower than for slalom chromatography, SEC back pressures of 2000-3000 psi are sufficient to change the delicate balance of maintaining the shape of molecules leading to resistance for their free movement especially when they do not fit into the pore orifices.WBD (US) 4908-4035-4214vlW-4803-W01
[0005] Apart from high pressure, the molecules can also get stuck in pores because of nonideal interactions with column stationary phase leading to incomplete elution and entrapment inside the column stationary phase. Repeated injections without complete recovery or analyte entrapment inside the column may lead to continued deteriorating column performance. Further, as biological buffers are more prone to microbial contamination, microbial growth inside a column may also lead to poor performance, including poor separation and recovery. In such cases, regeneration of columns for optimal performance is not generally feasible. As such, there is a need in the art for methods for restoring column chromatography performance.Summary of Technology
[0006] The present technology is directed to the use of aliphatic polyamines such as spermidine, norspermidine and spermine to condense unfolded or trapped nucleic acid molecules, including large high molecular weight DNA molecules, into compact and ordered structures so that they can pass through the narrow spaces flowing through a chromatography column. Similarly, lipid nano particles (LNP) with various size ranges and surface chemistries undergo nonspecific interactions with column stationary phase material. In addition, the LNPs can get stuck in pores of the column stationary phase material due to lack of geometric fit. As a result of injecting the aliphatic polyamines onto a column, the present technology alleviates the decrease in performance associated with column clogging. Such condensation is facilitated, e.g., by the neutralization of negative charges on nucleic acids with multivalent cations like protonated spermidine. The present technology is particularly useful under slalom chromatography conditions. Usage of aliphatic polyamines such as spermidine, norspermidine and spermine is also used in the present technology to clear microbial contaminated column through multiple injections so that the original column performance is restored. That is, the present technology uses protonated aliphatic polyamines in a method of reducing bacterial contamination from a chromatographic column, thereby restoring the column performance.
[0007] Accordingly, in one aspect, disclosed herein is a method of eliminating biological macromolecule or lipid nanoparticle (LNP) residues from a chromatographic column. The method comprises: a) injection loading a cleaning agent onto the chromatographic column, the cleaning agent comprising one or more protonated 2WBD (US) 4908-4035-4214vlW-4803-W01aliphatic polyamines; and b) flowing the cleaning agent through the chromatographic column, thereby releasing biological macromolecule or LNP residues from the chromatographic column.
[0008] In some embodiments, the biological macromolecule residues comprise carbohydrate residues, lipid residues, protein residues, nucleic acid residues, or a combination thereof. In some embodiments, the nucleic acid residues comprise DNA, RNA, or a combination thereof. In some embodiments, the DNA is double-stranded DNA (dsDNA) or single-stranded DNA (ssDNA) molecules. In some embodiments, the RNA is double-stranded RNA (dsRNA) or single-stranded RNA (ssRNA) molecules.
[0009] In some embodiments, the LNP residues comprise LNPs for mRNA delivery.
[0010] In some embodiments, including all the previous embodiments, the chromatographic column is a size exclusion chromatography column or a slalom chromatography column.
[0011] In some embodiments, including all the previous embodiments, the one or more aliphatic polyamines of the cleaning agent are selected from spermidine, norspermidine, and spermine.
[0012] In some embodiments, including all the previous embodiments, the one or more aliphatic polyamines are at concentration of at about 0.3 M to about 2 M. In some embodiments, the one or more aliphatic polyamines are at concentration of about 1 M.
[0013] In some embodiments, including all the previous embodiments, injection loading the cleaning agent comprises injection loading a volume of cleaning agent between 0.1 pL and 20 pL. In some embodiments, injection loading the cleaning agent comprises injection loading a volume of cleaning agent of about 2 pL. In some embodiments, injection loading the cleaning agent comprises injection loading a volume of cleaning agent of about 5 pL. In some embodiments, injection loading the cleaning agent comprises injection loading a volume of cleaning agent of about 10 pL.
[0014] In some embodiments, the method of eliminating biological macromolecule or LNP residues from a chromatographic column further comprises repeating steps a) and b) to eliminate at least 95% of the biological macromolecule residues from the chromatographic column. In some embodiments, steps a) and b) are repeated between 1 and 3 times to eliminate at least 95% of the biological macromolecule residues.3WBD (US) 4908-4035-4214vlW-4803-W01
[0015] In another aspect, disclosed herein is a method of reducing bacterial contamination from a chromatographic column. The method comprises: a) injection loading a cleaning agent onto the chromatographic column, the cleaning agent comprising one or more protonated aliphatic polyamines; b) flowing the cleaning agent through the chromatographic column; and c) repeating steps a) and b) between 10 and 20 times to reduce bacterial contamination from the chromatographic column.
[0016] In some embodiments of the above aspect, step c includes repeating steps a) and b) 15 times.
[0017] In some embodiments, including all the previous embodiments, the chromatographic column is a size exclusion chromatography column or a slalom chromatography column.
[0018] In some embodiments, including all the previous embodiments, the one or more aliphatic polyamines are selected from spermidine, norspermidine, and spermine.
[0019] In some embodiments, including all the previous embodiments, the one or more aliphatic polyamines of the cleaning agent are at concentration of at about 0.3 M to about 2 M. In some embodiments, the one or more aliphatic polyamines of the cleaning agent are at concentration of about 1 M.
[0020] In some embodiments, including all the previous embodiments, injection loading the cleaning agent comprises injection loading a volume of cleaning agent between 0.1 pL and 20 pL.Brief Description of the Drawings
[0021] The technology will be more fully understood from the following detailed description taking in conjunction with the accompanying drawings.
[0022] FIG. 1A-FIG. 1D provide a set of chromatograms illustrating a method to restore slalom chromatography performance using spermidine injections according to embodiments of the present technology. Repeated injections of DNA under slalom chromatography conditions (-10,000 psi) inhibit the recovery of injected sample over a period of time. Including spermidine injections in between chromatographic runs removes the nucleic acids stuck in the stationary phase, thereby maintaining the recovery and column performance.4WBD (US) 4908-4035-4214vlW-4803-W01
[0023] FIG. 1A provides a chromatogram illustrating a 5-injection 1 kbplus dsDNA ladder using GTx Resolve Premier Slalom 250 A, 2.5 pm column (available from Waters Technologies Corporation).
[0024] FIG. 1B provides a chromatogram illustrating the results after a 0.3M spermidine injection following the 5-injection ladder provided in FIG. 1 A.
[0025] FIG. 1C provides a chromatogram of 1 kbplus dsDNA using GTx Resolve Premier Slalom 250 A, 2.5 pm column (2-pL injection).
[0026] FIG. 1D provides a chromatogram illustrating the results after a 1 M spermidine injection (2 pL) following the 2-pL injection shown in FIG. 1C. The results indicate that the 1 M spermidine injection successfully released stuck dsDNA from the column stationary phase.
[0027] FIG. 2A-FIG. 2C provide a set of chromatograms demonstrating that a single injection of spermidine is sufficient to remove the stuck nucleic acid during slalom chromatography. After 5 injections of DNA ladder (FIG.2A), spermidine injections were made at 1 M concentration (FIG. 2B and FIG. 2C). While the first injection (0.5 mL / min flow rate for 6 min) exhibited appreciable UV (A260nm=0.013) signal between 1.5-2.2 min, the second injection exhibited little or no UV signal (<0.0015) indicating that 1 injection is sufficient to release the DNA stuck on the column.
[0028] FIG. 2A provides a chromatogram illustrating a 5-injection 1 kbplus dsDNA ladder using GTx Resolve Premier Slalom 250 A, 2.5 pm column.
[0029] FIG. 2B provides a chromatogram illustrating the results after a first 1 M spermidine injection following the 5 injections shown in FIG. 2A. The results indicate that the 1 M spermidine injection successfully released stuck dsDNA from the column stationary phase.
[0030] FIG. 2C provides a chromatogram illustrating the results after a second 1 M spermidine injection, indicating that one (1) injection was sufficient to release the DNA stuck on the column.
[0031] FIG. 3A-FIG. 3B provide a set of chromatograms illustrating slalom chromatography performance deterioration with repeated injections of large DNA species.
[0032] FIG. 3A provides a chromatogram of 15 consecutive injections of Hindlll digest of A DNA, showing minimal change in peak areas.5WBD (US) 4908-4035-4214vlW-4803-W01
[0033] FIG. 3B provides a graph illustrating changes in peak area (performance) with repeated injections (94 A DNA digest injections). A progressive decline in peak area was observed after the 15thinjection.
[0034] FIG. 4A-FIG. 4F provide a set of chromatograms demonstrating that spermidine injections released DNA stuck on slalom chromatography runs.
[0035] FIG. 4A provides a chromatogram of a spermidine injection, demonstrating that spermidine injection (by itself) does not contribute to the UV signal in the elution time range of dsDNA.
[0036] FIG. 4B provides a chromatogram illustrating separation of DNA components from Hindi 11 digest of A DNA by slalom chromatography.
[0037] FIG. 4C provides a chromatogram illustrating the results of a spermidine (1 M, 10 pL) injection after 6 injections of A DNA digest.
[0038] FIG. 4D provides a chromatogram illustrating the results of a spermidine (1 M, 10 pL) injection after 94 injections of A DNA.
[0039] FIG. 4E provides a chromatogram illustrating the results of blank (10 pL) injection after spermidine injection.
[0040] FIG. 4F provides a graph illustrating changes in column pressure over time after repeated injections of A DNA digest injections (94 injections) and a spermidine injection.
[0041] FIG. 5A-FIG. 5B provide a set of chromatograms demonstrating that inclusion of a spermidine injection in between slalom chromatography runs ensured consistent performance of injected analytes.
[0042] FIG. 5A provides a chromatogram illustrating an overlay of chromatography traces from 10 injections of A DNA digest following spermidine (1 M, 10 pL) injection (0.5 mL / min flow rate for 6 min) and column conditioning (30 min, 1.41 mL / min).
[0043] FIG. 5B provides a graph illustrating inclusion of spermidine injections maintained the column backpressure variation within 100 psi.
[0044] FIG. 6 provides a chromatogram illustrating a comparison of Cas9 mRNA signal before column contamination, after contamination, and after treatment with spermidine injection.
[0045] FIG. 7 provides a chromatogram illustrating an overlay of chromatography traces for 1st, 5th, 10th, and 15thspermidine (1M, 10 pL) injections, demonstrating that6WBD (US) 4908-4035-4214vlW-4803-W01the signal associated with the released material progressively decreased over 15 injections.
[0046] FIG. 8A-FIG. 8G provide a set of chromatograms demonstrating the removal of lipid nanoparticle (LNP) residues with spermidine injections (1 M, 5 pL).
[0047] FIG. 8A provides a chromatogram illustrating a blank injection of 5mM phosphate buffer to indicate the base line level signal (<0.0) at A260 nm.
[0048] FIG. 8B provides a chromatogram illustrating the inclusion of spermidine injection not contributing to the LNP signal.
[0049] FIG. 8C provides a chromatogram illustrating the inclusion of COMIRNATY® COVID-19 vaccine LNP injection showing A260 signal at retention time different from spermidine. A total of 5 injections were made, and 5thinjection chromatogram is provided herein.
[0050] FIG. 8D provides a chromatogram illustrating the inclusion of spermidine injection that released the trapped LNP as indicated by elevated A260 signal at LNP elution time.
[0051] FIG. 8E provides a chromatogram illustrating the inclusion of 2ndinjection and illustrating that an elevated signal at LNP elution time is not present.
[0052] FIG. 8F provides a chromatogram illustrating the inclusion of the 3rd spermidine injections and that an elevated signal at LNP elution time is not present.
[0053] FIG. 8G provides a chromatogram illustrating the inclusion blank injection (5mM phosphate buffer) with baseline signal.Detailed Description
[0054] Disclosed herein are methods of restoring column chromatography performance using injections of one or more aliphatic polyamines such as spermidine, norspermidine, and spermine. In order that the technology may be more readily understood, certain terms are first defined. It should be noted that whenever a value or range of values of a parameter are recited, it is intended that values and ranges intermediate to the recited values are part of this disclosure. The word “about” if not otherwise defined means ± 5%. It is also to be noted that as used herein and in the claims, singular forms of “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. Additional terms are defined throughout the specification.7WBD (US) 4908-4035-4214vlW-4803-W01Definitions
[0055] As used herein, the term “biological macromolecule” refers to a large, organic molecule such as carbohydrates, lipids, proteins, and nucleic acids.
[0056] As used herein, the term "lipid nanoparticle" or "LNP" refers to a nanoparticle composed of lipids and a nucleic acid payload. A lipid nanoparticle may comprise one or more types of lipids, including ionizable lipids (such as ionizable cationic lipids), phospholipids, structural lipids (such as cholesterol), and pegylated lipids. Lipids suitable for use in lipid nanoparticle compositions are further described in U.S. Patent No. 11 ,786,607, PCT publication WO 2017 / 223135, and U.S. Patent No. 10,507,249 each of which are incorporated herein by reference.
[0057] The term “aliphatic,” as used herein, includes saturated and unsaturated, straight chain (i.e. , unbranched) or branched aliphatic hydrocarbons that are optionally substituted with one or more functional groups. As will be appreciated by one skilled in the art, “aliphatic” as used herein is understood to include, but is not limited to, alkyl, alkenyl, and alkynyl moielies.
[0058] As used herein, the term “alkyl” refers to C1-C10 linear and branched alkyl groups. An analogous convention applies to other generic terms such as “alkenyl,” “alkynyl” and the like. Alkyl groups include, but are not limited to, for example, methyl, ethyl, n-propyl, isopropyl, allyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, tert-pentyl, n-hexyl, sec-hexyl, moieties and the like, which may have one or more substituents. Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-l-yl and the like. Representative alkynyl groups include, but are not limited to, ethynyl, 2-propynyl (propargyl), 1-propynyl and the like.
[0059] As used herein, the term “aliphatic polyamine” refers to a linear or branched aliphatic compound having at least two amino groups (primary or secondary amino groups) directly attached to the aliphatic moiety.
[0060] As used herein, the term “slalom chromatography” refers to a chromatographic method performed under high-flow conditions that separates a molecule by size based on hydrodynamic phenomena. The principles of slalom chromatography are further described in Hirabayashi and Kasai, J. Chromatogr. A (1996) 722(1 -2):135-42 and Hirabayashi eta!., Biochemistry (1990) 29(41 ):9515-21.8WBD (US) 4908-4035-4214vlW-4803-W01
[0061] The high-flow rates used in slalom chromatography (SC) afford sufficiently high shear rates that result in prolonged extension of the molecules, e.g., nucleic acids, which is important for the separation of the molecules by size. Said extension can be assessed using the Weissenberg number. The Weissenberg number is a dimensionless metric that is a function of relaxation time and shear rate:Wi = rRywherein TRis the relaxation time (seconds) as represented by the formula:nL2cIPTR =^T~wherein h is dynamic velocity (Pa*s); Leis contour length (m); IPis persistence length (m); ks is the Boltzmann constant (1.38x1 O’23J.K’1), and T is temperature (Kelvin); andY is shear rate (seconds-1) as represented by the formula:Au 16y=_= y < U> / dwherein Au is the velocity difference between two points in a direction perpendicular to the flow direction, the two points separated by a distance of Az; is the average linear interstitial velocity along the packed bed; and d is the average flow-through tube diameter.
[0062] The relaxation time TRis dependent, in part, on intrinsic properties of the target nucleic acid. In certain instances, the relaxation time of a molecule under certain conditions is known in the art. For example, the Lc of linear dsDNA is equal to the number of base pairs * 3.4 A; the dynamic velocity of linear dsDNA is 1.2 cP; and the persistence length of linear dsDNA is 450 A. Alternatively, relaxation time of a molecule under certain conditions may be determined empirically using known methods that are readily understood by one of ordinary skill in the art. (see, e.g., Bouchiat et al., Biophysical Journal (1999) 76:409-413).
[0063] The term “Size Exclusion Chromatography” or (SEC) is a type of chromatography in which the analytes (e.g., biological macromolecule as well as potential impurities) in a sample are separated or isolated on the basis of hydrodynamic radius ( / .e., size). In SEC, separation occurs because of the differences in the ability of analytes to probe the volume of the porous stationary phase media.9WBD (US) 4908-4035-4214vlW-4803-W01See, for example, A. M. Striegel et. al. Modern Size-Exclusion Chromatography: Practice of Gel Permeation and Gel Filtration Chromatography, 2nd Edition, Wiley, NJ, 2009. SEC is typically used for the separation of large molecules or complexes of molecules.
[0064] As used herein, the term “nucleic acids” or “nucleic acid molecules” refers to a polymeric molecule comprising two or more nucleotides. Nucleic acids may comprise deoxyribonucleic acids (DNA), ribonucleic acids (RNA), or a combination thereof. DNA comprises the nucleotides cytidine, guanosine, adenosine, and thymidine. RNA comprises the nucleotides cytidine, guanosine, adenosine, and uridine. In some embodiments, the nucleic acid molecules may comprise nucleic acid analogues (i.e. , non-naturally occurring nucleic acids or analogues thereof). Examples of nucleic acid analogues include peptide nucleic acids, locked nucleic acids, glycol nucleic acids, threose nucleic acids, hexitol nucleic acids. Nucleic acid analogues are further reviewed in Wang et al., Molecules (2023) 28(20):7043. Nucleic acid molecules may further be modified at the nucleobase, sugar, or phosphodiester backbone with an array of chemical modifications which are further reviewed in Epple et al., Emerg. Top. Life. Sci. (2021) 5(5):691 -697.
[0065] Nucleic acid molecules range in length as measured by the number of nucleotides or base pairs. In embodiments of the present technology, the nucleic acids may range from about 5000 base pairs to about 100,000 base pairs. Nucleic acids may be single stranded (e.g., single-stranded DNA (ssDNA) or single-stranded RNA (ssRNA)). In some embodiments, the ssRNA is mRNA. Nucleic acids may be double stranded (e.g., double-stranded DNA (dsDNA) or double-stranded RNA (dsRNA). Double-stranded nucleic acids are made of complementary sequences (e.g., basepaired sequences) as is known in the art and would be readily understood by one of ordinary skill.
[0066] Nucleic acids may be present in different topologies, including linear and circular conformations. In some embodiments, circular nucleic acids may be supercoiled, in which the circular nucleic acid molecule undergoes additional twist strain.10WBD (US) 4908-4035-4214vlW-4803-W01Methods and Conditions for Restoring Column Chromatography Performance Using Aliphatic Polyamine Injections
[0067] The present technology is directed to cleaning chromatography columns to restore performance. A method in accordance with an embodiment of the present technology restores column performance by removing trapped molecules that have undergone a shape change within the column and have, as a result, become entrapped within narrow spaces or passageways in the column. A method in accordance with another embodiment of the present technology cleans contaminated columns to restore their performance.
[0068] The present technology includes methods in which a cleaning agent comprising one or more protonated aliphatic polyamines is injection loaded onto a chromatography column (typically after the column has been previously used or held in a storage state for a period of time). The cleaning agent is flowed through the chromatography column to release biological macromolecule or LNP residues trapped therein or to reduce bacterial contamination from the chromatographic column.
[0069] The present technology is particularly useful in the fields of separating biological macromolecules such as nucleic acids (i.e., dsDNA, dsRNA, ssDNA, ssRNA) especially under slalom chromatography conditions. The present technology is also useful in the fields of separating LNPs. In certain embodiments, the technology restores column performance by removing trapped biological macromolecules or LNPs from the column. In other embodiments, the technology is used to clean the columns from microbial contamination that can occur as the result of using storage solutions or contaminated samples.Method of Eliminating Biological Macromolecule or Lipid Nanoparticle (LNP) Residues from a Chromatographic Column
[0070] In one aspect, disclosed herein is a method for eliminating biological macromolecule or LNP residues from a chromatographic column (FIG. 1A-FIG. 5B and FIG. 8A-FIG. 8G, respectively). Typically, repeated injections of DNA or other nucleic acid containing samples under slalom chromatography conditions (-10,000 psi) inhibit the recovery of injected sample over a period of time. Similarly, continued injections of LNPs without the release of trapped particles lead to deteriorating column11WBD (US) 4908-4035-4214vlW-4803-W01performance. Without wishing to be bound by theory, it is believed that the protonated aliphatic polyamines used in the methods of the present technology remove the nucleic acids or LNPs stuck in the stationary phase, thereby maintaining the recovery and column performance. For example, methods which include spermidine injections (or other protonated aliphatic polyamines) in between chromatographic runs remove the nucleic acids or LNPs stuck in the stationary phase.
[0071] According to some embodiments of the technology, the method comprises: a) injection loading a cleaning agent onto the chromatographic column, the cleaning agent comprising one or more protonated aliphatic polyamines; and b) flowing the cleaning agent through the chromatographic column, thereby releasing biological macromolecule or LNP residues from the chromatographic column.
[0072] Biological macromolecule residues comprise carbohydrate residues, lipid residues, protein residues, nucleic acid residues (e.g., RNA, DNA), or a combination thereof. These residues can unfold or be stretched while within the columns, especially when under slalom chromatography conditions and can become trapped, clogging flow through the column, such as a size exclusion chromatography column or a slalom chromatography column.
[0073] LNPs are valuable vehicles to deliver nucleic acids (e.g., siRNA, mRNA, and the like) as therapeutic agents and vaccines for the treatment or prevention of diseases and disorders, including viral infections and certain cancers. For example, the current COVID-19 mRNA vaccines from Pfizer-BioNTech and Moderna utilize LNPs to encapsulate mRNA, shield it from destructive enzymes, and shuttle it into cells. LNPs are generally prepared by encapsulating a nucleic acid with four lipid components (ionizable / cationic, phospholipid, cholesterol, and a pegylated lipid) through electrostatic interactions. Due to the fragile nature, delicate structural integrity, and extreme differences in physicochemical properties of the various LNPs and their components, analytical characterization by techniques such as size exclusion chromatography (SEC) with multi-angle light scattering (MALS) detection pose major challenges such as dissociation, poor-quality separation, poor sample recovery, and column fouling or clogging.
[0074] To remove the trapped residues, a cleaning agent is injection loaded onto the column. The cleaning agent includes one or more protonated aliphatic polyamines. In some embodiments, the one or more protonated aliphatic polyamines 12WBD (US) 4908-4035-4214vlW-4803-W01is selected from spermidine, norspermidine, and spermine. Chemical structures for spermidine, norspermidine, and spermine are provided below.NH2H2N NHSpermidine;norspermidine and;Spermine.
[0075] Various concentrations of the cleaning agent were investigated. In general, concentration values of at about 0.3 M to about 2 M of the cleaning agent provided desirable results. In some embodiments, the one or more aliphatic polyamines within the clean agent are at concentration of about 1 M.
[0076] Injection loading volumes were also investigated. Methods of the present technology typically involve injection loading a volume of cleaning agent between 0.1 pL and 20 pL. As known in the art, injection volume may depend at least on column dimension. In some embodiments, injection loading the cleaning agent comprises injection loading a volume of cleaning agent of about 2 pL. In some embodiments, injection loading the cleaning agent comprises injection loading a volume of cleaning agent of about 10 pL.
[0077] In some embodiments, the method of eliminating biological macromolecule or LNP residues from a chromatographic column further comprises repeating the injection loading and flowing of the cleaning agent (i.e., steps a) and b) provided above) to eliminate the biological macromolecule or LNP residues trapped in the chromatographic column. For example, steps a) and b) can be repeated between 1 and 3 times (i.e., 2 to 4 cycles) to eliminate at least 95% of the biological macromolecule or LNP residues trapped therein. In some embodiments, steps a) and b) are repeated between 1 and 3 times to eliminate at least 99% of the biological 13WBD (US) 4908-4035-4214vlW-4803-W01macromolecule or LNP residues.Method of Removing Bacterial Contamination from a Chromatographic Column
[0078] In another aspect, disclosed herein is method for removing bacterial contamination from a chromatographic column. Biological buffers, such as column storage buffers, are known to foster microbial contamination and microbial growth inside chromatography columns. This type of contamination leads to poor performance including separation and recovery. The present technology includes methods of reducing bacterial contamination through the repeated injections of protonated aliphatic polyamines, such as spermidine.
[0079] According to an aspect of the technology, the method comprises: a) injection loading a cleaning agent onto the chromatographic column, the cleaning agent comprising one or more protonated aliphatic polyamines; b) flowing the cleaning agent through the chromatographic column; and c) repeating steps a) and b) between 10 and 20 times to reduce bacterial contamination from the chromatographic column.
[0080] In a particular embodiment, it was found that if the injection loading and flowing steps were repeated 15 times, bacterial contamination was essentially eliminated, and column performance was restored. That is, after repeating steps a) and b) above 15 times, a previously contaminated column’s performance was restored to be consistent with or have the same performance as an uncontaminated column.
[0081] Various concentrations of the cleaning agent were investigated in connection with this aspect of the method. In general, concentration values of about 0.3 M to about 2 M of the one or more aliphatic polyamines within the cleaning agent provided desirable results. In some embodiments, the one or more aliphatic polyamines within the clean agent are at concentration of about 1 M.
[0082] Injection loading volumes were also investigated. Methods of the present technology typically involve injection loading a volume of cleaning agent between 0.1 pL and 20 pL. As known in the art, injection volume may depend at least on column dimension. In some embodiments, injection loading the cleaning agent comprises injection loading a volume of cleaning agent of about 2 pL. In some embodiments, injection loading the cleaning agent comprises injection loading a volume of cleaning agent of about 5 pL. In some embodiments, injection loading the cleaning agent comprises injection loading a volume of cleaning agent of about 10 pL.14WBD (US) 4908-4035-4214vlW-4803-W01Chromatography Systems
[0083] The methods disclosed herein may be used with any high-performance liquid chromatography (HPLC) or ultra-high performance liquid chromatography (UHPLC) system. Said systems comprise a column comprising a plurality of particles. The plurality of particles may be porous or non-porous. In some embodiments, the porous or non-porous particles are inorganic silica particles, organic particles, or inorganic / organic hybrid particles. Examples of particles suitable for use include, but are not limited to, ethylene bridged hybrid particles (BEH; comprising tetraethoxysilane (TEOS) and bis(triethoxysilyl)ethane as described in U.S. Patent No. 6,686,035, and 7,250,214, incorporated herein by reference. Additional particle compositions include, for example, hybrid inorganic / organic particles such as those described in U.S. Patent No. 11 ,291,974 and U.S. Patent No. 9,145,481. Additional particles may include polystyrene, divinylbenzene, polyacrylamides, and polymethylacrylates with varying degrees of crosslinking.
[0084] As described above, the plurality of particles may comprise a diameter of between about 1 pm and about 10.5 pm. In some embodiments, the plurality of particles comprises a diameter of between about 1-2 pm, 2-3 pm, 3-4 pm, 4-5 pm, 5-6 pm, 6-7 pm, 7-8 pm, 8-9 pm, 9-10 pm, or 10-10.5 pm. In some embodiments, the plurality of particles comprises a diameter of between about 1.5 - 1.9 pm. In some embodiments, the plurality of particles comprises a diameter of between about 2.8 -3.2 pm. In some embodiments, the plurality of particles comprises a diameter of about 1.7 pm. In some embodiments, the plurality of particles comprises a diameter of about 2.0 pm. In some embodiments, the plurality of particles comprises a diameter of about 3.0 pm. In some embodiments, the plurality of particles comprises a diameter of about 8 pm.
[0085] In some embodiments, the particle comprises a negatively charged surface, which contributes to electrostatic repulsion of the negatively charged nucleic acid molecules and the particle surface. Without wishing to be bound by any particular theory, distance of the nucleic acid molecules from the particle surface sharpens peak widths and increases separation speed at a constant resolution. Said electrostatic repulsion can further be adjusted by altering the ionic strength of the mobile phase, e.g., by increasing or decreasing the salt content of the mobile phase. Examples of 15WBD (US) 4908-4035-4214vlW-4803-W01negatively charged surfaces include silanols, surface modifications with a silane comprising a pendant group that has a negative charge (e.g., COO’ or SOa’), the grafting of a negatively charged group onto a polymer particle, or a chemical modification of a polymer particle that results in the surface display of a negatively charged group as would be understood by one of ordinary skill in the art.
[0086] In some embodiments, the columns feature non-porous particles. Other embodiments feature porous particles. In these embodiments, analyte size becomes relevant to ki considerations. For instance, in embodiments in which analyte size e.g., length, width, volume, etc.) is larger than the size of individual pores within the particles, the ki value can be calculated and evaluated as described above. However, if the analyte size is less than the pore size (e.g., DNA size is less than the size of the porosity (e.g., 3000 A), then a correction is needed to account for the possible penetration of the analyte inside the particle volume. In that case involving particle porosity sized larger than the analyte, there would be a mixed retention mechanism shifting the value of the zone retention factor as calculated by the “universal retention factor formula,” defined herein and throughout as:^1=(1—0)^1, HDC + 0^1, SC + kl,SEC
[0087] In the above equation, ki.sEc , e.g., retention wherein size exclusion chromatography (SEC) principles are at play, may be defined by the following formula:l - ce( Rq( Rq\2\klsEC= — - £p 1 - 4.4(-^-) + 4.98 —\ ^mesoL'meso' / wherein Rgis the gyration radius of the DNA as defined below,Dmeso refers to the size of the mesopores on the particle, andwherein seis the inter-particle void fraction of the column, and £pis the internal porosity of the particle.
[0088] In the above equation, ki,HDc , e.g., retention wherein HDC principles are at play, may be defined by the following formula:1KL’HDC~ 7D \ 77D "1+ 2( ^) - 2.6981\Upore / \ \^pore / Jwherein DpOre refers to the average distance between particles, and wherein Drepis defined by the following formula:16WBD (US) 4908-4035-4214vlW-4803-W01' \3D |2K9 IDrep — 4\3and wherein Rgis the gyration radius as defined by:Rg = 0.116 * Lc057and <Lext> is the average extension length of the DNA under shear flow conditions.
[0089] In the above equation, ki,sc , e.g., retention wherein SC principles are at play, may be defined by the following formula:kl,SC — ( 1e Tc) *a* ^contourwherein a is a proportionality empirical constant independent of the contour length of the DNA (a =0.1 mm-1), TCis a characteristic shear stress of the DNA chain (TC=0.25 Pa for dsDNA)and the remaining variables are as defined above. In the context of the Universal Retention Factor Formula, ki,sc defines the variable <Lext>.
[0090] Without wishing to be bound by any particular theory, it is understood that multiple chromatographic principles may influence retention of an analyte (e.g., a DNA or RNA molecule) based on the size and relaxation time (ms) of the analyte. For example, under increased flow rate (i.e., high shear rates), analytes with longer relaxation times will have increased retention on a column. In this context, ki may be defined using the universal retention factor formula described above.
[0091] The column material may be stainless steel, polyetheretherketone (PEEK) lined steel, titanium, or a stainless alloy. Column inner diameters may range from about 2.1 mm to about 7.8 mm. Column lengths may range from about 10 mm to about 300 mm. Exemplary column dimensions include, but are not limited to, 2.1 x 20 mm, 2.1 x 50 mm, 2.1 x 100 mm, 2.1 x 150 mm, 4.6 x 50 mm, 4.6 x 100 mm, 4.6 x 150 mm, and 4.6 x 300 mm.
[0092] The choice of column and particle, particularly with respect to column length and particle size, is in part dependent on the size of the nucleic acid molecules to be separated and detected as would be appreciated and readily understood by one of ordinary skill in the art.17WBD (US) 4908-4035-4214vlW-4803-W01
[0093] According to embodiments of the present disclosure, the columns are connected in fluidic series to a detector. In one aspect, the detector is an ultraviolet (UV) or a tunable ultraviolet (TUV) detector. In some embodiments, the detector is a multi-angle light scattering (MALS) detector. In some embodiments, the UV or TUV detector measures at between 210 nm to 300 nm. In preferred embodiments, the UV or TUV detector measures at between 230 to 260 nm, or more preferably at 230 nm and 260 nm. Said wavelengths are known in the art to detect nucleic acid molecules, including DNA and RNA. Additional detectors, such as fluorescence spectroscopy or mass spectrometry detectors can be utilized in conjunction with the disclosed methods. The detectors can be used alone or in tandem and can be further adjusted to detect molecule(s) of interest. For example, and not by way of limitation, a fluorescence detector may be utilized if the sample comprises a fluorescent molecule of interest.ExamplesExample 1 : Optimization of spermidine concentration for column cleaning
[0094] In this example, concentration of spermidine for removing dsDNA from a column was investigated. A 1 kbplus dsDNA ladder sample was loaded on a slalom chromatography column (GTx Resolve Premier Slalom, 250 A 2.5 pm Column available from Waters Technologies Corporation) for separation. Five injections of this DNA ladder were loaded onto the column. After the fifth consecutive DNA injection, the column was loaded with a 2-pL injection of 0.3M or 1 M spermidine.
[0095] Including spermidine injections in between slalom chromatographic runs removed nucleic acids stuck in the stationary phase, thereby maintaining the recovery and column performance. The behavior was illustrated with 1 kbplus dsDNA ladder using GTx Resolve Premier Slalom 250 A, 2.5 pm Column (FIG. 1 A). After 5 injections of DNA ladder, spermidine injections were made at 0.3M (FIG. 1B) or 1 M concentration (FIG. 1C). While the 0.3M spermidine injection did not show appreciable UV (A260nm = 0.0013) signal, the 1 M injection exhibited a higher UV signal (A260 nm = 0.16) and a profile similar to the 1 kb DNA ladder (FIG. 1 D), indicating the spermidine at 1 M concentration can release stuck DNA in the column stationary phase.18WBD (US) 4908-4035-4214vlW-4803-W01Example 2: Single injection of spermidine is sufficient to remove stuck nucleic acid during slalom chromatography
[0096] In this example, the efficacy of spermidine injections at removing stuck nucleic acid during slalom chromatography was investigated. A 1 kbplus dsDNA ladder sample was loaded on the slalom chromatography column described in Example 1.5 Injections of this DNA ladder were loaded onto the column. After the fifth consecutive DNA injection, the column was loaded with a first 2-pL,1 M spermidine injection (0.5 mL / min flow rate for 6 min). The column was then loaded with a second 2-pL, 1 M spermidine injection (0.5 mL / min flow rate for 6 min).
[0097] FIG. 2A-FIG. 2C demonstrated that a single injection of spermidine is sufficient to remove stuck nucleic acid during slalom Chromatography. After 5 injections of DNA ladder (FIG. 2A), spermidine injections were made at 1 M concentration (2 pL). The spermidine first injection (0.5 mL / min flow rate for 6 min) exhibited appreciable UV (A260nm = 0.013) signal between 1.5-2.2 min (FIG. 2B).However, the second spermidine injection exhibited little or no UV signal (<0.0015) (FIG. 2C), indicating that a single injection ( / .e., the first injection) was sufficient to release the DNA stuck on the column.Example 3: Slalom chromatography performance deterioration with repeated injections of large DNA species
[0098] In this example, the effect of repeated injections of large DNA species on slalom chromatography performance was investigated. 94 consecutive injections of Hind 111 digest of A DNA were loaded onto an XBridge protein SEC 250A 2.5pm column (available from Waters Technologies Corporation) operated under slalom chromatography conditions. The results were evaluated to ascertain the effects on the 94 consecutive injections over column performance.
[0099] Slalom chromatography performance is normally deteriorated with repeated injections of large DNA species (FIG. 3A-FIG. 3D). While the first 15 injections of Hindi 11 digest of A DNA showed minimal change in peak areas (FIG. 3A), progressive decline in peak area was observed after the 15thinjection. Such decline in peak area is shown for the 9.4 kbp peak, which was repeatedly injected on column, and the changes in peak area were computed. Using 9.4 kbp peak as a marker, its peak area 19WBD (US) 4908-4035-4214vlW-4803-W01trend over 94 injections is shown in FIG. 3B. About a 39% decline in peak area was observed for the 9.4kbp peak.Example 4: Spermidine injection releases DNA stuck on slalom chromatography runs
[0100] In this example, the efficacy of spermidine injections at releasing DNA stuck on slalom chromatography run was further investigated. First, spermidine was loaded onto an XBridge protein SEC 250A 2.5pm (operated under slalom chromatography conditions) to confirm that spermidine does not contribute to the UV signal in the elution time range of dsDNA. Six consecutive injections of A DNA digest were then loaded onto the column. After the sixth consecutive A DNA digest injection, the column was loaded with a 10-pL, 1 M spermidine injection. The column from Example 3 was also loaded with a 10-pL, 1 M spermidine injection after 94 consecutive A DNA digest injections.
[0101] Spermidine injections released DNA residues stuck on chromatographic column during slalom chromatography runs (see, e.g., FIG. 4A-4F). As illustrated in FIG. 4A, a spermidine injection (by itself) does not contribute to the UV signal in the elution time range of dsDNA. A separation of DNA components from Hindi 11 digest of A DNA by Slalom chromatography is shown in FIG. 4B. No appreciable signal was detected following a spermidine (1 M, 10 pL) injection after 6 consecutive injections of A DNA digest (FIG. 4C). However, a spermidine (1 M, 10 pL) injection after 94 consecutive injections of A DNA digest released significant amount of DNA stuck on the column (see, UV signal of 0.09 in (FIG. 4D) compared to 0.002 in (FIG. 4A) or (FIG. 4C). The spermidine injection (0.5 mL / min flow rate for 6 min) after 94 injections of A DNA digest also relieved the column pressure by ~400 psi, bringing the column pressure back the number observed for first injection of A DNA (FIG. 4F). A blank injection following the spermidine (1 M, 10 pL) injection (after 94 injections of A DNA digest) confirmed that all the A DNA residues were released from the column after a single spermidine (FIG. 4 E).WBD (US) 4908-4035-4214vlW-4803-W01Example 5: Inclusion of spermidine injection in between slalom chromatography runs ensures consistent performance of injected analytes
[0102] In this example, the effect of the inclusion of a spermidine injection in between slalom chromatography runs was investigated. Ten consecutive injections of Hindll I digest of A DNA were loaded onto an XBridge protein SEC 250A 2.5pm under slalom chromatography criteria. The 10 consecutive injections of A DNA digest were followed by a spermidine (1 M, 10 pL) injection (0.5 mL / min flow rate for 6 min) and column conditioning (30 min, 1.41 mL / min). The series of injections were repeated 10 times (i.e. , 100 injections of the digest and 10 injections of the spermidine).
[0103] An overlay of chromatography traces from 10 injections of A DNA digest following spermidine (1 M, 10 pL) injection (0.5 mL / min flow rate for 6 min) and column conditioning (30 min, 1.41 mL / min) is shown in FIG. 5A. Inclusion of spermidine injections maintained the column backpressure within 100-psi variation (FIG. 5B).
[0104] Table 1 denotes the %RSD (Relative standard deviation) for each chromatographic peak across 100 injections. The RSD values for all the DNA components stayed below 3% under these conditions.Table 1 : % RSD over 100 injections of ADNA digest.2-2.3Peaks Kbp 4.3 Kbp 6.5 Kbp 9.4 Kbp 23 Kbp%RSD 2.38 3.78 2.16 2.25 2.36Example 6: Restoring size exclusion chromatography performance by spermidine injection
[0105] In this example, spermidine was used to restore size exclusion chromatography performance. A Cas9 mRNA (1 mg / mL, 5 pL) injection was loaded onto an XBridge protein SEC 250A 2.5pm. After the run, the column was contaminated by flushing the column with a contaminated buffer to briefly expose the column to bacterial contamination. The contaminated column was left uncapped overnight (for about 18 hours).
[0106] After flushing the contaminated column, the column was loaded with a Cas9 mRNA (1 mg / mL, 5 pL) injection (after fouling). The column was then loaded with 21WBD (US) 4908-4035-4214vlW-4803-W01consecutive spermidine injections (1 M, 10 pL / injection, for 15 injections) until performance was restored. The column was then loaded with a Cas9 mRNA (1 mg / mL, 5 pL) injection (after cleaning).
[0107] Size exclusion chromatography performance for mRNA purification was restored by spermidine injection. A comparison of Cas9 mRNA signal before column contamination, after contamination, and after treatment with spermidine injection are provided in FIG. 6. The UV signal (A260 nm) was around 0.28AU for Cas9 mRNA before column contamination. After fouling the signal dropped to 0.07AU, after spermidine injections (1 M, 10 pL / injection, 15 injections), the column returned to original state where the UV (A260 nm) signal for Cas9 mRNA returned to 0.28AU, indicating the utility of spermidine in restoring column performance for size exclusion chromatography conditions.
[0108] A new SEC column was flushed with the same contaminated buffer and left uncapped for 5 days. A poor performance was observed with the contaminated column during Cas9 mRNA purification. Performance was restored after consecutive spermidine injections (1 M, 10 pL / injection, 15 injections).Example 7: Spermidine injections release UV absorbing component stuck in the column stationary phase
[0109] In this example, the effect of spermidine injections on column bacterial contamination was investigated. Fifteen consecutive injections of spermidine (1 M, 10 pL) were loaded onto a contaminated column (i.e., column of Example 6).
[0110] Fifteen injections of spermidine (1 M, 10 pL) were injected with 2X PBS mobile phase. The first injection released significant amount UV absorbing component in the elution. This signal progressively decreased over 15 injections. The chromatographic traces for 1st, 5th, 10th, and 15thinjections are shown in FIG. 7.Example 8: Spermidine injections release lipid nanoparticle (LNP) residues stuck in the column stationary phase
[0111] In this example, the efficacy of spermidine injections at releasing LNP residues stuck in an SEC chromatography stationary phase was investigated. The SEC column was equilibrated in buffer at 40°C . A blank injection of buffer was loaded on the column (FIG.8A). Subsequently, 5 pL of 1 M spermidine was injected to observe 22WBD (US) 4908-4035-4214vlW-4803-W01the elution profile of the spermidine sample and identify the region where LNP would elute. The elution time at 13.1 minutes showed no peak presence (FIG.8B). Following this, five injections of the COMIRNATY® COVID-19 sample (COVID-19 Vaccine, mRNA, by BioNTech and Pfizer) were made (injection #5 is shown in FIG. 8C with elution time of 13.1 minutes) to illustrate the elution region. Next, three injections of 1 M spermidine were administered to remove residual LNP from the column (FIG. 8D-FIG. 8F). The first spermidine injection had the highest removal impact, starting with a baseline rise at approximately 10.1 minutes and continuing until 40 minutes (FIG.8D).Subsequent injections showed normalization to baseline as the LNP were cleared from the column. Finally, a buffer blank was run to bracket the analysis (FIG. 8 G).
[0112] Although the disclosure herein has been described with reference to particular examples, it is to be understood that these examples are merely illustrative of the principles and applications of the present disclosure. It is therefore to be understood that numerous modifications may be made to the illustrative examples and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the appended claims.WBD (US) 4908-4035-4214vl
Claims
W-4803-W01ClaimsWe claim:
1. A method for reducing bacterial contamination from a chromatographic column, the method comprising:a) injection loading a cleaning agent onto the chromatographic column, the cleaning agent comprising one or more protonated aliphatic polyamines;b) flowing the cleaning agent through the chromatographic column; and c) repeating steps a) and b) between 10 and 20 times to reduce bacterial contamination from the chromatographic column.
2. The method of claim 1 , wherein steps a) and b) are repeated about 15 times to reduce bacterial contamination from the chromatographic column.
3. The method of claim 1 or 2, wherein the chromatographic column is a size exclusion chromatography column or a slalom chromatography column.
4. The method of any of claims 1-3, wherein the one or more aliphatic polyamines are selected from spermidine, norspermidine, and spermine.
5. The method of any one of claims 1-4, wherein the one or more aliphatic polyamines of the cleaning agent are at concentration of at about 0.3 M to about 2 M.
6. The method of claim 5, wherein the one or more aliphatic polyamines of the cleaning agent are at concentration of about 1 M.
7. The method of any one of claims 1-6, wherein injection loading the cleaning agent comprises injection loading a volume of cleaning agent between 0.1 pL and 20 pL.
8. A method for eliminating biological macromolecule or lipid nanoparticle (LNP) residues from a chromatographic column, the method comprising:24WBD (US) 4908-4035-4214vlW-4803-W01a) injection loading a cleaning agent onto the chromatographic column, the cleaning agent comprising one or more protonated aliphatic polyamines; andb) flowing the cleaning agent through the chromatographic column, thereby releasing biological macromolecule or LNP residues from the chromatographic column.
9. The method of claim 8, wherein the biological macromolecule residues comprise carbohydrate residues, lipid residues, protein residues, nucleic acid residues, or a combination thereof.
10. The method of claim 9, wherein the nucleic acid residues comprise DNA, RNA, or a combination thereof.
11. The method of claim 10, wherein the DNA is double-stranded DNA (dsDNA) or single-stranded DNA (ssDNA) molecules.
12. The method of claim 10, wherein the RNA is double-stranded RNA (dsRNA) or single-stranded RNA (ssRNA) molecules.
13. The method of claim 8, wherein the LNP residues comprise LNPs for mRNA delivery.
14. The method of any one of claims 8-13, wherein the chromatographic column is a size exclusion chromatography column or a slalom chromatography column.
15. The method of any one of claims 8-14, wherein the one or more aliphatic polyamines of the cleaning agent are selected from spermidine, norspermidine, and spermine.
16. The method of any one of claims 8-15, wherein the one or more aliphatic polyamines are at concentration of at about 0.3 M to about 2 M.25WBD (US) 4908-4035-4214vlW-4803-W0117. The method of any one of claims 8-16, wherein the one or more aliphatic polyamines are at concentration of about 1 M.
18. The method of any one of claims 8-17, wherein injection loading the cleaning agent comprises injection loading a volume of cleaning agent between 0.1 pL and 20 pL.
19. The method of claim 18, wherein injection loading the cleaning agent comprises injection loading a volume of cleaning agent of about 2 pL.
20. The method of claim 8, further comprising repeating steps a) and b) to eliminate at least 95% of the biological macromolecule residues from the chromatographic column.
21. The method of claim 20, wherein steps a) and b) are repeated between 1 and 3 times to eliminate at least 95% of the biological macromolecule residues.26WBD (US) 4908-4035-4214vl
